Enovis Corp Q3: Revenue, Profit Surpass Estimates
Update: 2025-11-06
Description
Enovis Corporation, a medical technology company, reported strong third-quarter results for 2025, exceeding Wall Streets revenue expectations. The companys sales increased by 8.6% to $548.9 million, with non-GAAP profit per share rising by 15.6% to $0.75. Enovis reaffirmed its full-year revenue guidance of $2.26 billion and raised its adjusted earnings per share guidance to $3.18, a 1.6% increase. Despite a negative operating margin, the companys free cash flow margin improved significantly to 5.3%. The stock remained flat at $31.50, indicating a neutral market reaction. Analysts anticipate a slight deceleration in growth for the next twelve months, but Enoviss newer products and services still point to continued success.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
